FDA orders J&J to cite death risks with taking Natrecor

04/26/2005 | NYTimes.com

Johnson & Johnson is changing the packaging insert for its heart failure drug, Natrecor, to state an increased risk of death associated with the medicine. The firm acted on orders from the FDA that notified Scios, J&J's subsidiary that makes the drug, that the information intended for professionals needed to be revised, citing at least seven published journal studies.

View Full Article in:

NYTimes.com

Published in Brief:

SmartBrief Job Listings for Health Care